R1 Therapeutics Ltd

R1 Therapeutics Ltd, based in the US, develops innovative therapies aimed at improving patient outcomes for those suffering from kidney disease, particularly focusing on hyperphosphatemia associated with chronic kidney disease (CKD). R1 Therapeutics Ltd specializes in the development of therapies for kidney disease. Founded in Redwood City, US in 2025, the company has raised USD 77. 5 mn in its Series A funding round as of March 17, 2026.

This funding round was co-led by Abingworth, F-Prime Capital, and DaVita Venture Group, with participation from other investors such as Curie. Bio, Symbiosis, and U. S. Renal Care, Inc.

R1 Therapeutics has completed one deal to date, reflecting a focused strategy on advancing their therapeutic offerings in the renal space. R1 Therapeutics specializes in developing innovative therapies for patients with kidney disease, primarily focused on hyperphosphatemia associated with chronic kidney disease (CKD). The company's lead product, AP306, is a first-in-class pan phosphate transporter inhibitor designed to block the active transport of phosphate in the gastrointestinal tract, targeting three key transporters: NaPi-IIb, PiT-1, and PiT-2. This mechanism aims to provide rapid phosphate lowering while reducing treatment burden for patients who rely on traditional phosphate binders.

The primary end-users of AP306 are CKD patients, particularly those undergoing dialysis, with anticipated geographical markets including the United States and potential expansion to regions with high kidney disease prevalence. R1 Therapeutics operates in the biotechnology sector, particularly within the renal therapeutics market. The revenue model relies on partnerships with healthcare providers and pharmaceutical collaborations, including licensing agreements for AP306. As a prescription medication, AP306 is expected to be marketed to hospitals, dialysis centers, and specialty pharmacies serving CKD patients.

The company has raised USD 77. 5 mn in Series A financing, indicating strong investor confidence in its business model and product pipeline, and plans to engage in B2B arrangements to facilitate the distribution of their flagship product. R1 Therapeutics plans to utilize the recent funding to advance the global development of AP306, including conducting a Phase 2b clinical study and supporting regulatory and manufacturing activities for treating hyperphosphatemia in chronic kidney disease patients. The company is also exploring opportunities to expand its market presence, targeting additional geographical regions to enhance accessibility to its therapies.

The successful completion of the clinical study and subsequent regulatory approvals will be crucial for the company to broaden its footprint in the renal therapeutics market.